SML2276
TH-263
≥98% (HPLC)
Synonym(s):
4-[(Phenylamino)sulfonyl]-N-(phenylmethyl)benzamide, N-Benzyl-4-(benzylsulfamoyl)benzamide
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C20H18N2O3S
CAS Number:
Molecular Weight:
366.43
UNSPSC Code:
12352200
SMILES string
O=C(C1=CC=C(C=C1)S(NC2=CC=CC=C2)(=O)=O)NCC3=CC=CC=C3
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Biochem/physiol Actions
Inactive analog control for the type III allosteric LIM-kinase (LIMK) inhibitors TH-251, TH-255 and TH-257.
TH263 is an inactive analog control for the type III allosteric LIM-kinase (LIMK) inhibitors TH-257, TH-255 and TH-251. For characterization details of the active probe, TH-257, please visit the TH-257 probe summary on the Structural Genomics Consortium (SGC) website.
TH-257, the active probe, is available from Sigma. To learn more about and purchase TH-257, click here.
To learn about other SGC chemical probes, visit sigma.com/sgc
TH-257, the active probe, is available from Sigma. To learn more about and purchase TH-257, click here.
To learn about other SGC chemical probes, visit sigma.com/sgc
Features and Benefits
TH-236 is a negative control for TH-257, a chemical probe available through a partnership with the Structural Genomics Consortium (SGC). To learn more and view other SGC chemical probes, visit sigma.com/SGC
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Risa Kashima et al.
Science signaling, 10(477) (2017-05-04)
Fragile X syndrome (FXS) is the most common cause of heritable intellectual disability and autism and affects ~1 in 4000 males and 1 in 8000 females. The discovery of effective treatments for FXS has been hampered by the lack of
Nicole C Goodwin et al.
ACS medicinal chemistry letters, 6(1), 53-57 (2015-01-16)
The first allosteric, type III inhibitor of LIM-kinase 2 (LIMK2) is reported. A series of molecules that feature both an N-phenylsulfonamide and tertiary amide were not only very potent at LIMK2 but also were extremely selective against a panel of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service